TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06284590: Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

Sponsor: Philogen S.p.A. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 162 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06284590 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06284590 Rescue Dossier →